Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Regeneron
About
Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
- Tarrytown,New York,United States
- 5001 - 10000
- http://www.regeneron.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $8.90M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 1988
- Number Of Employee
- 5001 - 10000
- Operating Status
- Active
- Stock Symbol
- nasdaq:REGN
- Legal Name
- Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 22, 2016 | Post-IPO Equity | $8.90M | 1 |
U.S. Department of Health & Human Services
|
— | Detail |
| Apr 12, 1991 | IPO | — | — | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 6, 2023
2seventy bio
|
Post-IPO Equity | $20M | Biotechnology | Yes |
|
May 17, 2022
Vyriad
|
Series B | $29.50M | Biotechnology | — |
|
Nov 9, 2021
Female Invest
|
Seed | $4.50M | E-Learning | — |
|
Jun 9, 2020
DNAnexus
|
Series G | $100M | Bioinformatics | — |
|
Sep 2, 2019
Adicet Bio
|
Series B | $80M | Biopharma | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
U.S. Department of Health & Human Services
|
Yes | Post-IPO Equity |
Employee Profiles
Exits
Regeneron has had 3 exits. Regeneron most notable exits include 2seventy bio , Decibel Therapeutics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Nov 5, 2021 | 2seventy bio | IPO | Biotechnology | Detail |
| Feb 11, 2021 | Decibel Therapeutics | IPO | Biotechnology | Detail |
| Jun 4, 2004 | Alnylam Pharmaceuticals | IPO | Biotechnology | Detail |
Acquisition
Regeneron has acquired 1 organizations. Their most recent acquisition was Checkmate Pharmaceuticals on Apr 19, 2022. They acquired Checkmate Pharmaceuticals for $250M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Apr 19, 2022
Checkmate Pharmaceuticals
|
Biotechnology | acquisition | $ 250M | Detail |
